Gastroenterology Department, Children, Youth and Women's Health Service, 72 King William Road, North Adelaide, SA 5006, Australia.
Dig Dis Sci. 2012 Apr;57(4):887-96. doi: 10.1007/s10620-011-1979-1. Epub 2011 Dec 7.
Current treatments for the inflammatory bowel diseases, encompassing Crohn's disease and ulcerative colitis, are variably effective. Emu oil, extracted from emu fat, predominantly comprises fatty acids, with purported claims of anti-inflammatory properties.
We evaluated emu oil for its potential to ameliorate dextran sulphate sodium (DSS)-induced colitis in rats.
Male Sprague-Dawley Rats were allocated to treatment groups (n = 8). Groups 1 and 2 consumed water and were gavaged (1 ml) daily with water (group 1) or emu oil (group 2) from days 0 to 10. Groups 3-6 ingested 2% DSS in the drinking water from days 5 to 10 and were gavaged from days 0 to 10 with water (group 3), 0.5 ml emu oil (group 4) or 1 ml emu oil (group 5). Group 6 received 1 ml emu oil after commencing DSS treatment (days 6-10). Disease activity index, metabolic parameters, (13)C-sucrose breath test, and histological colonic damage severity and crypt depth were assessed.
Emu oil in DSS-treated rats reduced colonic damage severity compared to DSS-controls (up to threefold; P < 0.001). In DSS-treated rats, crypts in the proximal colon were lengthened by 0.5 ml emu oil (373 ± 18 μm), compared with DSS-controls (302 ± 8 μm); whilst in the distal colon (DSS control: 271 ± 17 μm), crypt depth was greater following 0.5 ml emu oil (352 ± 22 μm) and 1 ml emu oil (341 ± 9 μm) and also when emu oil was administered post-DSS commencement (Group 6: 409 ± 16 μm; P < 0.05). Emu oil did not significantly affect other parameters of colonic architecture.
Emu oil improved tissue damage associated with colitis, suggesting its potential as a unique formulation to augment conventional treatment approaches for IBD.
目前治疗炎症性肠病（包括克罗恩病和溃疡性结肠炎）的方法效果各不相同。鸸鹋油从鸸鹋脂肪中提取，主要由脂肪酸组成，据称具有抗炎特性。
我们评估鸸鹋油对大鼠葡聚糖硫酸钠（DSS）诱导结肠炎的潜在治疗作用。
雄性 Sprague-Dawley 大鼠被分配到治疗组（n=8）。第 1 组和第 2 组分别饮用普通水和每日 1ml 普通水（第 1 组）或鸸鹋油（第 2 组），从第 0 天到第 10 天。第 3-6 组在第 5 天到第 10 天饮用含 2% DSS 的饮用水，并从第 0 天到第 10 天分别接受普通水（第 3 组）、0.5ml 鸸鹋油（第 4 组）或 1ml 鸸鹋油（第 5 组）灌胃。第 6 组在开始 DSS 治疗（第 6-10 天）后接受 1ml 鸸鹋油灌胃。评估疾病活动指数、代谢参数、13C-蔗糖呼气试验和组织学结肠损伤严重程度和隐窝深度。
与 DSS 对照组相比，DSS 治疗大鼠的结肠损伤严重程度在接受鸸鹋油治疗后降低（高达三倍；P<0.001）。在 DSS 治疗的大鼠中，近端结肠的隐窝在接受 0.5ml 鸸鹋油治疗后延长（373±18μm），而 DSS 对照组为 302±8μm；在远端结肠（DSS 对照组：271±17μm），接受 0.5ml 鸸鹋油（352±22μm）和 1ml 鸸鹋油（341±9μm）以及在开始 DSS 治疗后给予鸸鹋油（第 6 组：409±16μm）后，隐窝深度更大（P<0.05）。鸸鹋油对结肠结构的其他参数没有显著影响。
鸸鹋油改善了与结肠炎相关的组织损伤，表明其作为一种独特的配方，可能增强对炎症性肠病的传统治疗方法。
